The long-term, exclusive pharmaceutical category agreement is ... and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission.

Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing ...

In 2005, Sandoz became the world leader in generic pharmaceuticals after acquiring Germany's Hexal AG and US-based Eon Labs. The same year, Novartis acquired the North American over-the-counter ...

UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that Yehia Hashad, M.D., executive vice ...

Novel Modes of Treatment and Drugs Spur the Demand in the Immuno-oncology Market: Fact Report ROCKVILLE, MD, UNITED STATES, March 13, ...

New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.

Moderna Inc., a biotechnology and pharmaceutical company reorienting its business for a post-pandemic age, awarded almost $17 ...

Pertussis Treatment Market Pertussis Medications and Vaccinations Leading Therapeutic Approaches Driving Stance of Companies in the Market: ...

Q4 2024 Earnings Call Transcript March 7, 2025 Operator: Good morning, and welcome to the Molecular Partners Fourth Quarter ...

Strategic Company DecisionCuratis Announces Formation of Distinguished Advisory Board 11.03.2025 / 07:00 CET/CESTMEDIA RELEASELiestal, Switzerland, 11 March 2025: Curatis Holding (SIX:CURN) announces ...